

Partners

u^b

UNIVERSITÄT
BERN

KATHOLIEKE UNIVERSITEIT
LEUVEN



UNIVERSITE
D'Auvergne
CLERMONT - FD 1



Pioneering personalized medicine®

JOHANNES
GUTENBERG
UNIVERSITÄT
MAINZ



UNIVERSITY OF GOTHENBURG

UNIVERSITY OF
Southampton
School of Medicine



UNIVERSITÀ degli STUDI di ROMA
TOR VERGATA



IBD_{ase}



Contact:

Dr. Daniel Lottaz (Coordinator)
email: daniel.lottaz@insel.ch

www.ibdase.org

Mucosal Proteases and their Inhibitors
in Inflammatory **B**owel **D**isease

Mucosal Proteases and their Inhibitors in Inflammatory Bowel Disease


IBD_{ase}

From etiopathogenetic insight to innovative therapy


The IBDase project studies the causes and mechanisms of actions of Inflammatory Bowel Disease (IBD). IBD is a group of chronic inflammatory conditions of the intestine. The two main IBD disease entities are Crohn's disease and ulcerative colitis. Environmental and genetic factors cause the disease.




The project envisages a multidisciplinary approach, linking genetic studies in IBD patients with functional studies in cell culture and IBD animal models. We search for new diagnostic tools and therapies focused on protein-cleaving enzymes (proteases) of the intestinal mucosa and their inhibitors.



Environment (bacteria)



Genetic (proteases)



IBDase groups nine research institutions from eight different countries, including an industrial partner. IBDase runs for three years, starting from March 1st, 2008.

IBDase has come into existence thanks to a grant from the European Commission 7th Framework Programme.



www.ibdase.org

